Razoxane

CAS No. 21416-67-1

Razoxane( 4,4'-propylenebis(piperazine-2,6-dione) )

Catalog No. M27828 CAS No. 21416-67-1

Razoxane is used as an antimitotic agent with immunosuppressive properties.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 285 Get Quote
10MG 402 Get Quote
25MG 664 Get Quote
50MG 888 Get Quote
100MG 1242 Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Razoxane
  • Note
    Research use only, not for human use.
  • Brief Description
    Razoxane is used as an antimitotic agent with immunosuppressive properties.
  • Description
    Razoxane is used as an antimitotic agent with immunosuppressive properties.(In Vivo):This tumor model is characterized by osteoid formation and spontaneous metastasization to lungs, kidneys and lymph nodes. Razoxane given intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation (30 mg/kg or 10 mg/kg per day) resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor. Early treatment with razoxane (30 mg/kg i.p. from day -2 to +14) showed a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Whereas 59.9 per cent of the total sectional area of the lungs in the control animals was covered by osteosarcoma metastases, only 3.4 per cent and 26.1 per cent respectively was affected in the early and late razoxane treatment groups. Toxic side-effects of these treatment schedules were reversible diffuse alopecia, but no retardation of body weight gain.
  • In Vitro
    Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
  • In Vivo
    Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation). Animal Model:Sprague-Dawley ratsDosage:30 mg/kg or 10 mg/kg per day Administration:Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result:Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
  • Synonyms
    4,4'-propylenebis(piperazine-2,6-dione)
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    Topoisomerase
  • Recptor
    ——
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    21416-67-1
  • Formula Weight
    268.273
  • Molecular Formula
    C11H16N4O4
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(CN1CC(=O)NC(=O)C1)N1CC(=O)NC(=O)C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.KunchengQiu, et al. Protective effect of total glycosides from lily on H2O2-induced H9C2 cells mitochondrial damage and characterization of the chemical profiles by UHPLC-LTQ-Orbitrap-MSn. Journal of Functional Foods. Volume 71, August 2020, 104036
molnova catalog
related products
  • LMP744 hydrochloride

    LMP744 hydrochloride is a DNA intercalator and Topoisomerase I (Top1) inhibitor with antitumor activity.?

  • Proscillaridin A

    Proscillaridin A is a natural product.It is a potent poison of topoisomerase I/II activity with IC50 values of 30 nM and 100 nM, respectively.

  • Marbofloxacin

    Marbofloxacin is a potent antibiotic inhibiting bacterial DNA replication.